← Back![Gila Therapeutics, Inc. Logo](/_next/image?url=https%3A%2F%2Fs3-us-west-2.amazonaws.com%2Fmedical-alley-association-data-interface%2FmemberLogos%2F62191.jpg%3F1721707378530&w=1080&q=75)
![Gila Therapeutics, Inc. Logo](/_next/image?url=https%3A%2F%2Fs3-us-west-2.amazonaws.com%2Fmedical-alley-association-data-interface%2FmemberLogos%2F62191.jpg%3F1721707378530&w=1080&q=75)
Partner
PARTNER DIRECTORY
Gila Therapeutics, Inc.
62191
Location: MINNEAPOLIS, MN
Pharmaceuticals
About this partner
Clinical-stage phase II • Delivering natural gut hormones via novel “topical lingual” delivery platform.
Novel topical lingual delivery technology leverages unexploited biological pathway “neural targeting via lingual activation”
by application of micro-dose natural peptides to the tongue • Activates the satiety centers of the brain while avoiding nausea centers • Raising $35m to conduct OUS proof of concept studies with primary endpoint of total weight loss at 3 months in multiple placebo-controlled RCTs • Gila will deliver first PYY to market • Gila platform’s breakthrough risk-benefit profile enables new drug combinations and treatment targets.